Literature DB >> 10837528

Preparation of peptide and protein powders for inhalation.

.   

Abstract

Innovations in biotechnology and recombinant techniques have led to a large increase in the number of macromolecule drugs developed over the last several years. These molecules are enabling new therapies for many previously untreated or poorly treated diseases. Due to poor oral absorption, most biopharmaceuticals are delivered by injection. Medical science, health care providers and consumers have been searching for alternative methods of delivering macromolecule drugs. Animal and human clinical studies have demonstrated that pharmacological doses of bioactive peptides and proteins pass, by a natural biological process, from the lungs into the bloodstream or local tissue. New macromolecule drugs are also being developed for treatment of respiratory diseases such as cystic fibrosis, adult and infant respiratory distress syndromes, asthma and emphysema. This paper reviews formulations for delivering therapeutic aerosols to the lungs. Particular emphasis will be placed on preparing fine powders containing macromolecule drugs.

Entities:  

Year:  1997        PMID: 10837528     DOI: 10.1016/s0169-409x(97)00506-1

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  19 in total

1.  Formation and isolation of spherical fine protein microparticles through lyophilization of protein-poly(ethylene glycol) aqueous mixture.

Authors:  T Morita; Y Horikiri; H Yamahara; T Suzuki; H Yoshino
Journal:  Pharm Res       Date:  2000-11       Impact factor: 4.200

Review 2.  Pharmaceutical particle engineering via spray drying.

Authors:  Reinhard Vehring
Journal:  Pharm Res       Date:  2007-11-28       Impact factor: 4.200

3.  Development of budesonide microparticles using spray-drying technology for pulmonary administration: design, characterization, in vitro evaluation, and in vivo efficacy study.

Authors:  Sonali R Naikwade; Amrita N Bajaj; Prashant Gurav; Madhumanjiri M Gatne; Pritam Singh Soni
Journal:  AAPS PharmSciTech       Date:  2009-08-01       Impact factor: 3.246

4.  The effects of excipients and particle engineering on the biophysical stability and aerosol performance of parathyroid hormone (1-34) prepared as a dry powder for inhalation.

Authors:  Sunday A Shoyele; Neeraj Sivadas; Sally-Ann Cryan
Journal:  AAPS PharmSciTech       Date:  2011-01-27       Impact factor: 3.246

Review 5.  Materials and methods for delivery of biological drugs.

Authors:  Alexander N Zelikin; Carsten Ehrhardt; Anne Marie Healy
Journal:  Nat Chem       Date:  2016-10-21       Impact factor: 24.427

6.  Delivery of pDNA Polyplexes to Bronchial and Alveolar Epithelial Cells Using a Mesh Nebulizer.

Authors:  Larissa Gomes Dos Reis; Maree Svolos; Lyn M Moir; Rima Jaber; Norbert Windhab; Paul M Young; Daniela Traini
Journal:  Pharm Res       Date:  2018-11-15       Impact factor: 4.200

7.  A Design of Experiment (DoE) approach to optimise spray drying process conditions for the production of trehalose/leucine formulations with application in pulmonary delivery.

Authors:  S Focaroli; P T Mah; J E Hastedt; I Gitlin; S Oscarson; J V Fahy; A M Healy
Journal:  Int J Pharm       Date:  2019-03-05       Impact factor: 5.875

Review 8.  Physical stability of dry powder inhaler formulations.

Authors:  Nivedita Shetty; David Cipolla; Heejun Park; Qi Tony Zhou
Journal:  Expert Opin Drug Deliv       Date:  2019-12-13       Impact factor: 6.648

9.  Proton-detected solid-state NMR spectroscopy of natural-abundance peptide and protein pharmaceuticals.

Authors:  Donghua H Zhou; Gautam Shah; Charles Mullen; Dennis Sandoz; Chad M Rienstra
Journal:  Angew Chem Int Ed Engl       Date:  2009       Impact factor: 15.336

10.  Characterization of a cyclosporine solid dispersion for inhalation.

Authors:  Gerrit S Zijlstra; Michiel Rijkeboer; Dirk Jan van Drooge; Marc Sutter; Wim Jiskoot; Marco van de Weert; Wouter L J Hinrichs; Henderik W Frijlink
Journal:  AAPS J       Date:  2007-06-15       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.